Smulkiųjų ląstelių plaučių vėžio imunoterapija

Despite permanent scientific activity and research, limited progress has been made in more than two decades in the treatment of small-cell lung cancer (SCLC). The prognosis of SCLC remains poor. SCLC is a very immunogenic tumor with high somatic mutation numbers, immunosuppressive status. According to the recently published clinical trials, two immune-checkpoint inhibitors – atezolizumab and durvalumab, significantly prolong overall survival in this disease without additional safety concerns.